Weight-Loss Drug Access Lowest in Areas With Highest Obesity Rates
Source Summary
Private prescription data from England reveals that Wegovy and Mounjaro, weight-loss medications offering substantial results without surgery, are prescribed at lower rates in communities where obesity is most prevalent. This disparity highlights an access divide in private healthcare provision for obesity treatment.
Why it matters
The disparity indicates that private healthcare markets may not serve populations with the greatest medical need, potentially widening health inequalities.
